Nasus Pharma grants CFO Nir Sassi options on 115K shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nasus Pharma Ltd CFO Nir Sassi was granted options to purchase 115,000 ordinary shares under the company’s 2019 Incentive Option Plan on November 11, 2026. The options have exercise prices of $3.50 for 38,333 shares, $4.00 for 38,333 shares, and $5.00 for 38,334 shares. Vesting spans 36 months: one-third on November 11, 2027, then the remaining two-thirds in eight equal quarterly installments beginning February 11, 2028. The options expire November 11, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Share options (right to buy) F1 | -- | -- | -- |
| Holding | Share options (right to buy) F1 | -- | -- | -- |
| Holding | Share options (right to buy) F1 | -- | -- | -- |
Footnotes (1)
- F1. On November 11, 2026, the Issuer granted options to purchase 115,000 ordinary shares, no par value ("Ordinary Shares"), under its 2019 Incentive Option Plan. The options vest over thirty-six (36) months: one-third on November 11, 2027, and the remaining two-thirds in eight equal quarterly installments beginning February 11, 2028. Any fractional shares resulting from vesting will be deferred to the next vesting tranche on a rolling basis.
Key Figures
Key Terms
2019 Incentive Option Plan financial
vesting financial
quarterly installments financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did Nasus Pharma (NSRX) CFO Nir Sassi receive?
When do Nir Sassi’s Nasus Pharma (NSRX) options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.